While these trials were not specifically designed to assess joint pain, patients with obesity-related joint pain who achieve significant weight loss through GLP-1 therapy often report improved mobility, reduced need for analgesics, and enhanced ability to engage in physical activitycreating a positive cycle of further weight management and joint health
Thats a 0.7% difference - less than a one percentage point absolute risk reduction
When it does occur, it's usually related to dry mouth, dietary changes, or ketosis during weight lossall of which are manageable with hydration and oral hygiene adjustments
Although compounded drugs are legal, they do not undergo pre-market approval from the FDA as they are tailored to individual orders from healthcare providers, potentially resulting in variations in dose, route of administration, and efficacy compared to commercially available drugs
Semaglutide, tirzepatide, and high dose dulaglutide have been deemed to have very high likelihood of achieving adequate blood sugar control, while other GLP-1s have been deemed highly likely
Component trials' stopping rules were defined for single-component administration and do not transfer.